ARCHIVES

NSABP’s Pink Sheet; Fisher’s Control Had A Downside, Review Said

This article is from The Cancer Letter archive.

Vol. 20 No. 25 | June 24, 1994

Download PDF Visit The Full Archive

Related Articles

FDA Committee Can’t Find “Reasonable” Evidence Alkylating Agent Clinical Use Is Carcinogenic

September 10, 1976

Funding Opporunities: Program Announcments

January 15, 1999

In Brief: Broder Invokes Cancer Act Provision To Inform Hammer, Bush Of Potential Damage Of 32% Cut

September 7, 1990

Funding Opportunities.

April 12, 2002

In Brief: Clinical Education Program to Be Phased Out; Ken Endicott Retires From Grupenhoff Firm

January 31, 1986

New NIH Grant Program or Young Investigators

October 8, 2010